These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2066 related items for PubMed ID: 27756875

  • 1. Eriocalyxin B, a natural diterpenoid, inhibited VEGF-induced angiogenesis and diminished angiogenesis-dependent breast tumor growth by suppressing VEGFR-2 signaling.
    Zhou X, Yue GG, Liu M, Zuo Z, Lee JK, Li M, Tsui SK, Fung KP, Sun H, Pu J, Lau CB.
    Oncotarget; 2016 Dec 13; 7(50):82820-82835. PubMed ID: 27756875
    [Abstract] [Full Text] [Related]

  • 2. Anti-angiogenic activity and mechanism of kaurane diterpenoids from Wedelia chinensis.
    Huang W, Liang Y, Wang J, Li G, Wang G, Li Y, Chung HY.
    Phytomedicine; 2016 Mar 15; 23(3):283-92. PubMed ID: 26969382
    [Abstract] [Full Text] [Related]

  • 3. Penduliflaworosin, a Diterpenoid from Croton crassifolius, Exerts Anti-Angiogenic Effect via VEGF Receptor-2 Signaling Pathway.
    Liang Y, Zhang Y, Wang G, Li Y, Huang W.
    Molecules; 2017 Jan 13; 22(1):. PubMed ID: 28098802
    [Abstract] [Full Text] [Related]

  • 4. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW, Lien JC, Kuo SC, Huang TF.
    Carcinogenesis; 2012 May 13; 33(5):1022-30. PubMed ID: 22436611
    [Abstract] [Full Text] [Related]

  • 5. Eriocalyxin B, a novel autophagy inducer, exerts anti-tumor activity through the suppression of Akt/mTOR/p70S6K signaling pathway in breast cancer.
    Zhou X, Yue GG, Chan AM, Tsui SK, Fung KP, Sun H, Pu J, Lau CB.
    Biochem Pharmacol; 2017 Oct 15; 142():58-70. PubMed ID: 28669564
    [Abstract] [Full Text] [Related]

  • 6. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models.
    Wu XY, Xu H, Wu ZF, Chen C, Liu JY, Wu GN, Yao XQ, Liu FK, Li G, Shen L.
    Oncotarget; 2015 Dec 29; 6(42):44563-78. PubMed ID: 26575424
    [Abstract] [Full Text] [Related]

  • 7. Dietary compound isoliquiritigenin inhibits breast cancer neoangiogenesis via VEGF/VEGFR-2 signaling pathway.
    Wang Z, Wang N, Han S, Wang D, Mo S, Yu L, Huang H, Tsui K, Shen J, Chen J.
    PLoS One; 2013 Dec 29; 8(7):e68566. PubMed ID: 23861918
    [Abstract] [Full Text] [Related]

  • 8. Cryptotanshinone inhibits VEGF-induced angiogenesis by targeting the VEGFR2 signaling pathway.
    Xu X, Wu L, Zhou X, Zhou N, Zhuang Q, Yang J, Dai J, Wang H, Chen S, Mao W.
    Microvasc Res; 2017 May 29; 111():25-31. PubMed ID: 28040437
    [Abstract] [Full Text] [Related]

  • 9. Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer.
    Wang N, Wang ZY, Mo SL, Loo TY, Wang DM, Luo HB, Yang DP, Chen YL, Shen JG, Chen JP.
    Breast Cancer Res Treat; 2012 Aug 29; 134(3):943-55. PubMed ID: 22350787
    [Abstract] [Full Text] [Related]

  • 10. Gamabufotalin, a major derivative of bufadienolide, inhibits VEGF-induced angiogenesis by suppressing VEGFR-2 signaling pathway.
    Tang N, Shi L, Yu Z, Dong P, Wang C, Huo X, Zhang B, Huang S, Deng S, Liu K, Ma T, Wang X, Wu L, Ma XC.
    Oncotarget; 2016 Jan 19; 7(3):3533-47. PubMed ID: 26657289
    [Abstract] [Full Text] [Related]

  • 11. Sulfated fucoidan FP08S2 inhibits lung cancer cell growth in vivo by disrupting angiogenesis via targeting VEGFR2/VEGF and blocking VEGFR2/Erk/VEGF signaling.
    Chen H, Cong Q, Du Z, Liao W, Zhang L, Yao Y, Ding K.
    Cancer Lett; 2016 Nov 01; 382(1):44-52. PubMed ID: 27569654
    [Abstract] [Full Text] [Related]

  • 12. Arenobufagin, a bufadienolide compound from toad venom, inhibits VEGF-mediated angiogenesis through suppression of VEGFR-2 signaling pathway.
    Li M, Wu S, Liu Z, Zhang W, Xu J, Wang Y, Liu J, Zhang D, Tian H, Li Y, Ye W.
    Biochem Pharmacol; 2012 May 01; 83(9):1251-60. PubMed ID: 22305746
    [Abstract] [Full Text] [Related]

  • 13. Anti-angiogenic effect of furanodiene on HUVECs in vitro and on zebrafish in vivo.
    Zhong ZF, Hoi PM, Wu GS, Xu ZT, Tan W, Chen XP, Cui L, Wu T, Wang YT.
    J Ethnopharmacol; 2012 Jun 01; 141(2):721-7. PubMed ID: 21911050
    [Abstract] [Full Text] [Related]

  • 14. Binding of Resveratrol to Vascular Endothelial Growth Factor Suppresses Angiogenesis by Inhibiting the Receptor Signaling.
    Hu WH, Duan R, Xia YT, Xiong QP, Wang HY, Chan GK, Liu SY, Dong TT, Qin QW, Tsim KW.
    J Agric Food Chem; 2019 Jan 30; 67(4):1127-1137. PubMed ID: 30525561
    [Abstract] [Full Text] [Related]

  • 15. A novel 2-aminobenzimidazole-based compound Jzu 17 exhibits anti-angiogenesis effects by targeting VEGFR-2 signalling.
    Lien JC, Chung CL, Huang TF, Chang TC, Chen KC, Gao GY, Hsu MJ, Huang SW.
    Br J Pharmacol; 2019 Oct 30; 176(20):4034-4049. PubMed ID: 31368127
    [Abstract] [Full Text] [Related]

  • 16. Salinomycin exhibits anti-angiogenic activity against human glioma in vitro and in vivo by suppressing the VEGF-VEGFR2-AKT/FAK signaling axis.
    Bi YL, Mi PY, Zhao SJ, Pan HM, Li HJ, Liu F, Shao LR, Zhang HF, Zhang P, Jiang SL.
    Int J Mol Med; 2017 May 30; 39(5):1255-1261. PubMed ID: 28358414
    [Abstract] [Full Text] [Related]

  • 17. Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects.
    Li D, Xie K, Zhang L, Yao X, Li H, Xu Q, Wang X, Jiang J, Fang J.
    Cancer Lett; 2016 Jul 28; 377(2):164-73. PubMed ID: 27130666
    [Abstract] [Full Text] [Related]

  • 18. ZLM-7 exhibits anti-angiogenic effects via impaired endothelial cell function and blockade of VEGF/VEGFR-2 signaling.
    Su M, Huang J, Li J, Qin X, Tang X, Jin F, Chen S, Jiang C, Zou Z, Peng K, Nuruzzaman M, Zhang J, Luo J, Liu S, Luo Z.
    Oncotarget; 2016 Apr 05; 7(14):19018-30. PubMed ID: 26967559
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.
    Li X, Wang X, Ye H, Peng A, Chen L.
    Cancer Chemother Pharmacol; 2012 Sep 05; 70(3):425-37. PubMed ID: 22814678
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 104.